Azithromycin ophthalmic solution, 1%

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Posterior Blepharoconjunctivitis

Conditions

Posterior Blepharoconjunctivitis

Trial Timeline

Nov 1, 2010 → Aug 1, 2011

NCT ID

NCT01220258

About Azithromycin ophthalmic solution, 1%

Azithromycin ophthalmic solution, 1% is a phase 2 stage product being developed by Merck for Posterior Blepharoconjunctivitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01220258. Target conditions include Posterior Blepharoconjunctivitis.

What happened to similar drugs?

4 of 5 similar drugs in Posterior Blepharoconjunctivitis were approved

Approved (4) Terminated (0) Active (1)

✅Ixekizumab Prefilled SyringeEli LillyApproved

✅AdalimumabAbbVieApproved

✅Esomeprazole + PlaceboAstraZenecaApproved

✅Sugammadex Injection [Bridion] + PlaceboMerckApproved

🔄Sham Injection + FAI InsertEyePoint PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01269658	Phase 2	Terminated	Dec 1, 2010	Jun 1, 2011	Blepharitis
NCT01220258	Phase 2	Terminated	Nov 1, 2010	Aug 1, 2011	Posterior Blepharoconjunctivitis
NCT01105624	Approved	Completed	Mar 1, 2010	Nov 1, 2010	Contact Lens Dry Eye
NCT01014078	Approved	Completed	Oct 1, 2009	Mar 1, 2010	Dry Eye Disease
NCT00894530	Phase 2	Completed	May 1, 2009	Dec 1, 2009	Blepharitis
NCT00892970	Phase 2	Completed	Apr 1, 2009	Jan 1, 2010	Blepharitis

Competing Products

10 competing products in Posterior Blepharoconjunctivitis

See all competitors

Product	Company	Stage	Hype Score
Ixekizumab Prefilled Syringe	Eli Lilly	Approved	39
Adalimumab	AbbVie	Approved	43
Esomeprazole + Placebo	AstraZeneca	Approved	43
Sugammadex Injection [Bridion] + Placebo	Merck	Approved	43
FTY720 + Oral Corticosteroid	Novartis	Phase 2	27
REGN7041	Regeneron Pharmaceuticals	Phase 1/2	39
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)	Baxter	Phase 2	32
ESK-001	Alumis	Phase 2	21
Sham Injection + FAI Insert	EyePoint Pharmaceuticals	Phase 3	34
CF101 + Placebo	Can Fite Biopharma	Phase 2	17